Levodopa/Carbidopa Retard Teva (Carbidopa, Levodopa)

Levodopa serves as a biochemical precursor that crosses the blood‑brain barrier and is converted into dopamine within central nervous system neurons. This conversion compensates for the dopamine deficiency that characterises Parkinson's disease, thereby restoring neurotransmission and alleviating motor deficits.

The specific dose and dosing schedule for Levodopa/Carbidopa Retard Teva are determined by the prescribing clinician based on the individual patient's disease severity, response to therapy, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Levodopa/Carbidopa in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually and discuss alternative options when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective oral therapy for symptomatic control of Parkinson’s disease because it directly replenishes central dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or alternatives, but they generally provide less robust motor improvement compared with the levodopa‑carbidopa combination.

Levodopa/Carbidopa Retard Teva tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually with a glass of water. It is often recommended to ingest the tablets on an empty stomach or with a light snack to optimise absorption, unless the prescriber advises otherwise. Patients should follow the timing and frequency prescribed by their healthcare professional.

Serious risks include neuroleptic malignant syndrome, severe psychiatric disturbances such as hallucinations or psychosis, and cardiovascular complications like arrhythmias or marked hypotension. Patients should be monitored closely for any sudden changes in mental status, severe muscle rigidity, fever, or unexplained drops in blood pressure.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors, and caution is advised for those with significant cardiovascular disease, uncontrolled hypertension, or a history of severe psychiatric illness.